Analysis of Designer Drugs Detected in the Products Purchased in Fiscal Year 2006
Nahoko Uchiyama, Ruri Kikura-Hanajiri, Nobuo Kawahara, Yukihiro Goda
YAKUGAKU ZASSHI October 1, 2008 DOI: 10.1248/yakushi.128.1499 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Analytical study Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Products purchased just before the amendment of the law |
| Citations | 46 |
| Key points | Seven designer drugs, including the newly identified 5-MeO-EIPT, were detected in 15 products purchased just before the law amendment. |
Abstract
Many psychotropic substances are easily available in Japan via the Internet, thus the spread of drug abuse is becoming more serious problem. To avoid drug abuse, 32 substances have been controlled in Japan since April in 2007 by the Pharmaceutical Affairs Law as designated substances (Shitei-Yakubutsu, classified as 11 tryptamines, 11 phenethylamines, 2 piperazines, 6 alkyl nitrites, 1 diterpene and 1 plant). Although the distributions of these drugs have been decreased through this regulation, new designer drugs are still being found. In this study, we detected 7 designer drugs in 15 products, which purchased just before the amendment of the law, by NMR, GC-MS and LC-MS analyses. Three methylone derivertives (1-(3,4-methylenedioxyphenyl-2-(pyrrolidin-1-yl)-1-pentanone: MDPV, 2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one: bk-MBDB, 2-ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one): bk-MDEA, a MDMA derivative (N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane: N-OH MDMA), a methamphetamine derivative (N-methyl-1-(4-fluorophenyl)propan-2-amine: N-Me-4-FMP), a tryptamine derivative (5-methoxy-N-ethyl-N-isopropyltryptamine: 5-MeO-EIPT) and indan-2-amine were detected. 5-MeO-EIPT was newly identified in this study.